¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Çѱ¹°£´ãÃé¿Ü°úÇÐȸ Á¦13Â÷ ±¹Á¦½Ì±ÛÅäÇȽÉÆ÷Áö¿ò : 2018-09-14

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
Çѱ¹°£´ãÃé¿Ü°úÇÐȸ Á¦13Â÷ ±¹Á¦½Ì±ÛÅäÇȽÉÆ÷Áö¿ò : 2018-09-14
±³À°ÀÏÀÚ : 2018-09-14
±³À°Àå¼Ò : ¿©¼ö ¿¥ºíÈ£ÅÚ 1Ãþ ±×·£µåº¼·ë  
±³À°ÁÖÁ¦ : Á¦13Â÷ ±¹Á¦½Ì±ÛÅäÇȽÉÆ÷Áö¿ò      
ÁÖÃÖ±â°ü : Çѱ¹°£´ãÃé¿Ü°úÇÐȸ
´ã´çÀÚ : À̺¸¹Ì
¿¬¶ôó : 02-2227-8299  
À̸ÞÀÏ : khbps@khbp.or.kr      
±³À°Á¾·ù : ¿Ü°ú      
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 4Á¡  
Áö¿ª : Àü¶ó³²µµ
±³À°½Ã°£ : 4 ½Ã°£ 40ºÐ  
¼¼ºÎ¼ö°­·á : 100,000¿ø      
ºñ°í [Æò»ýȸ¿ø,Á¤È¸¿ø] »çÀüµî·Ï: 50,000¿ø / ÇöÀåµî·Ï 70,000¿ø [Àü°øÀÇ, °£È£»ç, ±ºÀÇ°ü] »çÀüµî·Ï: 30,000¿ø / ÇöÀåµî·Ï 50,000¿ø [ºñȸ¿ø] »çÀüµî·Ï: 70,000¿ø / ÇöÀåµî·Ï: 100,000¿ø      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 12:40~12:50 Introduction: Posthepatectomy Liver Failure (PHLF)  ¹Ú»óÀç(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 12:50~13:10 Various factors associated with liver regeneration after hepatectomy  ±è¼¼ÁØ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 13:10~13:30 Quantified risk assessment of PHLF in cirrhotic liver  Á¤µ¿È¯(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 13:30~13:50 Impact and prediction of chemotherapy-associated liver injury  ÇÑ´ëÈÆ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 13:50~14:10 Risk prediction of PHLF in patients with perihilar cholangiocarcinoma  ÃÖ»õº°(°í·ÁÀÇ´ë) 
Åä·Ð 09¿ù 14ÀÏ ±×·£µåº¼·ë 14:10~14:20 Discussion  () 
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 14:20~14:50 Virtual and augmented reality for image-guided surgery  Maki Sugimoto(International University of Health and Welfare) 
È޽Ġ09¿ù 14ÀÏ ±×·£µåº¼·ë 14:50~15:10 Coffee Break  () 
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 15:10~15:30 Knack and pitfall of various PVE techniques  °í±â¿µ(¿ï»êÀÇ´ë ¿µ»óÀÇÇаú) 
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 15:30~15:50 Outcome and safety of PVE between cirrhotic, cholestatic, and normal liver  ¾È±Ù¼ö(°è¸íÀÇ´ë) 
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 15:50~16:05 What next when PVE fails to induce enough hypertrophy?  ÀÓâ¼·(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 16:05~16:20 Drawback of PVE: oncologic perspectives  ÃÖ¿µ·Ï(ºÐ´ç¼­¿ï´ë) 
Åä·Ð 09¿ù 14ÀÏ ±×·£µåº¼·ë 16:20~16:30 Discussion  () 
È޽Ġ09¿ù 14ÀÏ ±×·£µåº¼·ë 16:30~16:40 Break  () 
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 16:40~16:55 Indication of PBD with regard to background liver, FLR and patient¡¯s condition  ±èÈñÁØ(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 16:55~17:10 Optimal preoperative bilirubin level with regard to background liver, FLR and patient¡¯s condition  ¼­ÇüÀÏ(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 17:10~17:25 Endoscopic biliary drainage: is it oncologically safe?  ±è¿ëÈÆ(°è¸íÀÇ´ë) 
±³À°½Ã°£ 09¿ù 14ÀÏ ±×·£µåº¼·ë 17:25~17:40 Simultaneous PVE and PBD; is it feasible?  È«ÅÂÈ£(°¡Å縯ÀÇ´ë) 
Åä·Ð 09¿ù 14ÀÏ ±×·£µåº¼·ë 17:40~17:50 Discussion  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Çѱ¹°£´ãÃé¿Ü°úÇÐȸ Á¦13Â÷ ±¹Á¦½Ì±ÛÅäÇȽÉÆ÷Áö¿ò : 2018-09-14""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ±¹¸³¾Ï¼¾ÅÍ ÀÇ·áÄ¿¹Â´ÏÄÉÀ̼Ǹ®´õ½Ê°úÁ¤ : 2018-09-15
´ÙÀ½±Û ºÎ»ê¼Ò¾Æ°úÇÐȸ Á¤±â Çмú Áý´äȸ : 2018-09-13
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
423 ¼­¿ï °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ Á¦ 12ȸ °¡Å縯¼ºÇü½ÉÆ÷Áö¾ö : 2018-09-09 0 785 2018-08-15
422 ¼­¿ï Á߾Ӵ뺴¿ø È£Èí±â¾Ë·¹¸£±â³»°ú ¿¬¼ö°­Á : 2018-09-09 1 753 2018-08-15
421 ¼­¿ï ´ëÇѼºÇü¿Ü°úÇÐȸ Ç׳ëÈ­¼ºÇü¿¬±¸È¸ Á¦4ȸ ½ÉÆ÷Áö¾ö : 2018-09-09 0 803 2018-08-15
420 ¼­¿ï ´ëÇѺñ¸¸ÇÐȸ Á¦1ȸ ºñ¸¸Àü¹®°¡ ½ÉÈ­°úÁ¤: ºñ¸¸ Àü¹® ÀÎÁ¤ÀÇ ±³À° Part 1. : 2018-09-09 0 579 2018-08-15
419 °æ±â ºÐ´ç¼­¿ï´ëÇб³º´¿ø 2018³â Çù·Âº´ÀÇ¿ø ÀÇ»ç ¿¬¼ö°­Á : 2018-09-09 0 1,357 2018-08-15
418 ¼­¿ï Á¦1ȸ ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ESD¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2018-09-08 0 868 2018-08-15
417 ¼­¿ï Á¦11ȸ ¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø ÁßȯÀÚÀÇÇÐ ¿¬¼ö°­Á Basic Concepts in Intensive Care, 2018 (BACIC 2018) : 2018-09-08 0 1,377 2018-08-15
416 ¼­¿ï ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ °í·Á´ëÇб³ °í°üÀý ½ÉÆ÷Áö¿ò : 2018-09-08 0 1,104 2018-08-15
415 ¼­¿ï 2018 ´ëÇÑ¿ä·Î»ý½Ä±â°¨¿°ÇÐȸ ¿öÅ©¼¥ : 2018-09-08 0 515 2018-08-15
414 ºÎ»ê ´ëÇѼ¼Æ÷º´¸®ÇÐȸ International Session of the 30th Annual Fall Meeting of the Korean Society for Cytopathology : 2018-09-08 0 590 2018-08-15
413 ºÎ»ê 2018³â ºÎ¿ï°æ³»ºÐºñ´ë»çÇÐȸ ´ç´¢º´±³À°ÀÚ ¼¼¹Ì³ª : 2018-09-08 0 1,040 2018-08-15
412 ±¤ÁÖ Àü³²´ëº´¿ø Á¦ 3Â÷ Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ½Å°æ°úÇб³½Ç ¿¬¼ö°­Á : 2018-09-08 0 1,091 2018-08-15
411 ºÎ»ê ºÎ»ê´ëº´¿ø 2018³â Á¦1Â÷ ¸ð¹ß¿¬¼ö±³À° (ÁÖÁ¦: Å»¸ðÁõÀÇ Áø´Ü°ú Ä¡·á) : 2018-09-08 0 1,432 2018-08-15
410 °æ±â ¾ÆÁÖ´ëÇб³º´¿ø Á¦6ȸ ¾ÆÁÖ ´ç´¢¹ß ¹× â»ó ½ÉÆ÷Áö¾ö : 2018-09-08 0 1,212 2018-08-15
409 ±¤ÁÖ 2018 Àü³²´ëÇб³º´¿ø ÁßȯÀÚÀÇÇнÉÆ÷Áö¿ò ¹× ±â°èȯ±â¿öÅ©¼ó : 2018-09-08 0 739 2018-08-15
1371 | 1372 | 1373 | 1374 | 1375 | 1376 | 1377 | 1378 | 1379 | 1380
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷